UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

Journal of clinical oncology, 2002-11, Vol.20 (21), p.4292-4302

2002

Volltextzugriff (PDF)

ZD1839 ('Iressa') as an anticancer agent

Drugs (New York, N.Y.), 2000, Vol.60 Suppl 1, p.33-40; discussion 41-2

2000

Volltextzugriff (PDF)

Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy

Annals of oncology, 2016-10, Vol.27 (10), p.1966-1969

2016

Volltextzugriff (PDF)

Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors

British journal of cancer, 2004-02, Vol.90 (3), p.566-572

2004

Volltextzugriff (PDF)

The tyrosine kinase inhibitor ZD1839 (iressa) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells

Cancer research (Chicago, Ill.), 2001-10, Vol.61 (19), p.7184-7188

2001

Volltextzugriff (PDF)

Flow of partially molten crust controlling construction, growth and collapse of the Variscan orogenic belt; the geologic record of the French Massif Central

Bulletin de la Société géologique de France, 2020, Vol.191, p.25

2020

Volltextzugriff (PDF)

Pressure-temperature conditions and significance of Upper Devonian eclogite and amphibolite facies metamorphisms in southern French Massif Central

Bulletin de la Société géologique de France, 2020, Vol.191, p.28

2020

Volltextzugriff (PDF)

Kinematics, deformation partitioning and late Variscan magmatism in the Agly Massif, eastern Pyrenees, France

Bulletin de la Société géologique de France, 2020, Vol.191 (1), p.15

2020

Volltextzugriff (PDF)

Zircon age of vaugnerite intrusives from the central and southern Vosges crystalline massif (E France); contribution to the geodynamics of the European Variscan belt

Bulletin de la Société géologique de France, 2020, Vol.191, p.26

2020

Volltextzugriff (PDF)

Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors

Annals of oncology, 2004-05, Vol.15 (5), p.831-838

2004

Volltextzugriff (PDF)

Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine

Annals of internal medicine, 1988-08, Vol.109 (4), p.267

1988

Volltextzugriff (PDF)

Structure of lamprophyres: a discriminant marker for Variscan and Alpine tectonics in the Argentera-Mercantour Massif, Maritime Alps

Bulletin de la Société géologique de France, 2019, Vol.190, p.12

2019

Volltextzugriff (PDF)

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2003-06, Vol.21 (12), p.2237-2246

2003

Volltextzugriff (PDF)

New bisphosphonates in the treatment of bone metastases

Cancer, 1993-12, Vol.72 (S11), p.3443-3452

Averbuch, Steven D.

1993

Volltextzugriff (PDF)

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

Journal of clinical oncology, 2002-05, Vol.20 (9), p.2240-2250

2002

Volltextzugriff (PDF)

Phase I Study of ZD9331 on Short Daily Intravenous Bolus Infusion for 5 Days Every 3 Weeks With Fixed Dosing Recommendations

Journal of clinical oncology, 2001-03, Vol.19 (5), p.1476-1484

2001

Volltextzugriff (PDF)

Interim results from a phase 1/2 precision medicine study of PLX8394- a next generation BRAF inhibitor

European journal of cancer (1990), 2020-10, Vol.138, p.S2-S3

2020

Volltextzugriff (PDF)

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition

Journal of clinical oncology, 2002, Vol.20 (1), p.110-124

2002

Volltextzugriff (PDF)

Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines

The Journal of infection, 2018-01, Vol.76 (1), p.20-37

2018

Volltextzugriff (PDF)

ZD1839, a Specific Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, Induces the Formation of Inactive EGFR/HER2 and EGFR/HER3 Heterodimers and Prevents Heregulin Signaling in HER2-overexpressing Breast Cancer Cells

Clinical cancer research, 2003-04, Vol.9 (4), p.1274-1283

2003

Volltextzugriff (PDF)

Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition

Journal of clinical oncology, 2002-01, Vol.20 (1), p.110-124

Albanell, J.

2002

Volltextzugriff (PDF)

L3.1 The Challenges of Drug-Diagnostic (RX-DX) Co-Development: A Biopharmaceutical Perspective

Annals of oncology, 2012-06, Vol.23, p.v6-v7

2012

Volltextzugriff (PDF)

Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine

Cancer, 1994-01, Vol.73 (2), p.432-436

1994

Volltextzugriff (PDF)

Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation

The lancet oncology, 2014-07, Vol.15 (8), p.e327-e340

2014

Volltextzugriff (PDF)

Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia

Journal of clinical oncology, 1993-08, Vol.11 (8), p.1618-1623

1993

Volltextzugriff (PDF)

1 – 25 von 1.752

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.263)
Mit Volltextzugriff
(1.364)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(813)
Life Sciences & Biomedicine
(412)
Humans
(351)
Physical Sciences
(262)
Exact Sciences And Technology
(214)
Female
(198)
Male
(186)
Technology
(175)
Physics
(166)
Computer Science
(141)
Biological And Medical Sciences
(140)
Adult
(136)
Medical Sciences
(129)
Condensed Matter: Structure, Mechanical And Thermal Properties
(122)
Structure Of Solids And Liquids; Crystallography
(120)
Structure Of Specific Crystalline Solids
(119)
Middle Aged
(109)
Chemistry
(96)
Neurosciences & Neurology
(92)
Inorganic Compounds
(87)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

IngentaConnect
(573)
Access via Wiley Online Library
(455)
Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
(409)
MEDLINE
(376)
Journals@Ovid Ovid Full Text
(368)
Single Journals
(368)
Access via ScienceDirect (Elsevier)
(306)
Wiley Online Library Full Collection 2018
(245)
EZB-NALI5-00465 Elsevier Archive NL
(220)
IngentaConnect Journals
(199)
IEEE Electronic Library (IEL)
(113)
Ebook Central Perpetual and DDA
(94)
eBooks on EBSCOhost
(90)
SpringerNature Journals
(76)
Nexis Uni
(69)
EZB-NALI2-00462 Springer Archive NL
(55)
Access via Oxford University Press
(39)
Nature
(38)
De Gruyter eBooks
(36)
De Gruyter journals
(33)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

ZD1839 ('Iressa') as an anticancer agent

Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy

Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors

The tyrosine kinase inhibitor ZD1839 (iressa) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells

Flow of partially molten crust controlling construction, growth and collapse of the Variscan orogenic belt; the geologic record of the French Massif Central

Pressure-temperature conditions and significance of Upper Devonian eclogite and amphibolite facies metamorphisms in southern French Massif Central

Kinematics, deformation partitioning and late Variscan magmatism in the Agly Massif, eastern Pyrenees, France

Zircon age of vaugnerite intrusives from the central and southern Vosges crystalline massif (E France); contribution to the geodynamics of the European Variscan belt

Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors

Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine

Structure of lamprophyres: a discriminant marker for Variscan and Alpine tectonics in the Argentera-Mercantour Massif, Maritime Alps

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

New bisphosphonates in the treatment of bone metastases

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

Phase I Study of ZD9331 on Short Daily Intravenous Bolus Infusion for 5 Days Every 3 Weeks With Fixed Dosing Recommendations

Interim results from a phase 1/2 precision medicine study of PLX8394- a next generation BRAF inhibitor

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition

Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines

ZD1839, a Specific Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, Induces the Formation of Inactive EGFR/HER2 and EGFR/HER3 Heterodimers and Prevents Heregulin Signaling in HER2-overexpressing Breast Cancer Cells

Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition

L3.1 The Challenges of Drug-Diagnostic (RX-DX) Co-Development: A Biopharmaceutical Perspective

Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine

Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation

Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia

Suchergebnisse filtern